LifeTech Capital Reiterates Neutral Rating on Echo Therapeutics Following Q2 Results

In a report published Monday, LifeTech Capital analyst Stephen M. Dunn reiterated a Neutral rating on Echo Therapeutics ECTE. In the report, LifeTech Capital noted, “Maintaining Neutral Rating: We continue to believe Echo's Symphony tCGM remains a world-class technology trapped under a cloud of management's failure to unlock any shareholder value despite clinical successes and key opinion leader support. The current lack of confidence of management's financial execution results in our Neutral rating for Echo as poor capital management on the next round of funding can be reasonably expected to offset any additional clinical progress with Symphony and thus we are unable to model Echo with any degree of confidence.” Echo Therapeutics closed on Friday at $2.40.